Healio: Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day Benefit of radiotherapy for nasopharyngeal carcinoma may vary by time of day Adjuvant therapy with camrelizumab significantly improved 3-year event-free survival in patients with locoregionally advanced nasopharyngeal carcinoma compared with observation, according to findings ... Nasopharyngeal carcinoma (NPC), a malignancy that develops in the upper section of the throat behind the nose, occurs in fewer than one person out of 100,000 worldwide each year. Locally advanced ...
Please provide your email address to receive an email when new articles are posted on . Patients with nasopharyngeal cancer who received morning radiotherapy survived longer than those treated later ... Oncology Nurse Advisor: Treatment-Related Thyroid Dysfunction Common With PD-1 Therapy for Nasopharyngeal Cancer Nasdaq: Akeso's Penpulimab Gets NMPA Approval For First-Line Treatment Of Nasopharyngeal Cancer (RTTNews) - Biopharmaceutical company Akeso Inc. (AKESF) said in a statement that its Penpulimab has been approved for the first-line treatment of recurrent or metastatic nasopharyngeal cancer or NPC, ...
